Acid price - Crack Key For U

25.09.2021 0 Comments

acid price  - Crack Key For U

Tranexamic acid is an antifibrinolytic drug used in the prevention and Fibrinolysis is a key component of the haemostatic processes that. Reduction of uric acid levels is key to avoiding gout flares. annually at a cost of nearly $1 billion.2 Risk factors include genetics. I can help you with your queries regarding Food Fortification, Edible Oil, Maha & Guj crack down on food adulteration, ace food safety initiatives Maha. acid price  - Crack Key For U

: Acid price - Crack Key For U

Bandicam crack + keygen - Free Activators
Wondershare recoverit crack 32 bit - Free Activators
Express vpn lifetime crack pc
Corel paintshop pro 2019 serial number and activation code - Free Activators

Low temperature activation of methane over a zinc-exchanged heteropolyacid as an entry to its selective oxidation to methanol and acetic acid

U. Patil, Y. Saih, E. Abou-Hamad, A. Hamieh, J. D. A. Pelletier and J. M. Basset, Chem. Commun., 2014, 50, 12348 DOI: 10.1039/C4CC04950K

To request acid price - Crack Key For U to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.


Is Anal Bleaching Worth the Bootylicious Hype?

Welcome to the wonderful world of butthole bleaching. We’re happy you could join us. Let’s begin with the basics.

Now that you know the lowdown, here’s a deep dive into all things anal bleaching.

DIY anal bleaching

You can totes bleach your bum at home. There are lots of creams, gels, and lotions available online or in beauty supply stores.

Keep in mind, everyone’s different. Those with allergies or sensitive skin might have a harsher reaction to the treatment. Def do a patch test before you go to town. Your booty will thank you later.

Safety first

Anal bleaching is perfectly safe when done correctly. Just be sure to only buy top-notch products. Bad brands can lead to infection, skin damage, and permanent skin discoloration.

ProductPSA: A lot of skin-lightening products — especially brands made outside the United States — aren’t regulated. So, you won’t always know what’s really going on with your body. And your anus is one area you don’t wanna mess with. (Trust us.)

Ingredients to look out for

Here’s what to look out for in a DIY anal bleaching product.

Malic acid: Naturally derived from fruits, this solution decreases pigmentation without the use of harsher chemicals like hydroquinone.

Kojic acid: This exfoliating acid has been approved for use in concentrations of 1 percent by the Cosmetic Ingredient Review Expert Panel. Bonus: It also has properties that may reduce the signs of skin aging.

Malic acid: This alpha-hydroxy acid (AHA) loosens the bonds between skin pigment cells. This allows the cells to flake off and expose paler skin.

Lactic acid: Got milk? This dairy-derived AHA is a dope way to even out skin tone and treat hyperpigmentation. BTW, you can’t pour milk down your butt crack. It has to be an actual lactic acid concentrate. 🐄

Emblica extract: Give your butt the best of both worlds with this Indian gooseberry serum. It’s a natural skin lightener and a killer source of vitamin C.

DIY should work just fine, but you might get better results going to a skin care pro. They have access to stronger and better-quality products. Plus, they’re trained to bleach your butt. This might reduce your risk of side effects.

Professional bleaching

Sure you’ll pay more… but your anus deserves the best.

Is it permanent?

Anal bleaching results don’t last forever. Daily activities — like walking, running, sweating, and sitting — can cause chafing or friction. This can lead to more pigmentation.

DIY treatments have the shortest butt-shelf life. You need to touch it up every 1 or 2 months. Professional-grade treatments usually last a bit longer.

Laser treatments usually give the longest results. You only need a touch up every 6 months to 1 year.

FYI: Results vary from anus to anus.

How to find a provider

Talk to your dermatologist or doctor before getting a treatment. They can confirm that you don’t have underlying health issues.

Once you get the all-clear, you can check out local:

  • spas
  • salons
  • plastic surgery centers

Some offer both topical and laser anal bleaching treatments.

How to prep for your appointment

Pre-procedure rules are super simple. Here are some important tips.

  • Don’t sweat it. Avoid activities like hot yoga and hardcore cardio a few days before your bleach sesh. Sweating might make the treatment less effective.
  • Ditch the thong. Tight underwear — especially the up your butt-crack variety — can lead to friction.
  • Avoid hair removal. Waxing, shaving, or Nair-ing can irritate the skin around your anus.
  • Don’t get your freak on. Sex can lead to tiny tears in your anal region. This increases your risk of discomfort during and after your bleaching treatment. So, avoid anal or vajayjay sex for at least 3 days before your visit.

Here’s what to do the day of your appointment:

  • Gently clean the area around your bum.
  • Wear loose clothing to avoid excess friction.
  • Take an over-the-counter (OTC) pain killer (e.g. ibuprofen) beforehand.

Great ass-expectations (what to expect from the procedure)

Here’s a play-by-play of what happens during your appointment.

  1. You might be asked to fill out an intake form upon acid price - Crack Key For U. This helps your provider learn more about your skin.
  2. They will take you to the treatment room.
  3. You’ll be asked to remove your bottoms and lie on your back.
  4. They might ask you to roll your legs to one side. This makes it easier for them to get to your rectal region.
  5. Your provider will apply a cream, gel, or chemical peel to your anal area. They might give you a numbing cream if you opt for a laser treatment.
  6. Voilà! Once they’re done, you can get dressed and take your new bleached butthole out for a spin.

Good news! The entire anal bleaching process should take less than 30 minutes. The exact timing depends on your service and provider.

After care

Most folks recover from anal bleaching in about a week. But it can be faster or longer depending on your skin and what kind of treatment you received. Here are some helpful healing tips.

Products: Your provider will probably send you home with a cream, lotion, or gel to help soothe the area and kick-start the recovery process.

Patience: Give your booty-hole time to heal. Avoid any activities that lead to friction. You should also wear loose fitted bottoms for a minimum of 3 days. This can help prevent inflammation and may reduce your risk of infection.

Do I need to avoid sex?

Don’t have sex for at least 3 days after your treatment. This helps prevent irritation and infections. Continue to abstain if your skin still feels raw or irritated after day 3.

Laser bleaching

Laser treatments break down dark skin pigments into smaller particles. These cells then get carried off by white blood cells.

You might see results after your first treatment. But you prob need to have it done 3 or 4 times for the best results. After that it’s all about upkeep. Get a touch up every 6 months to 1 year to maintain the look.

What does laser bleaching feel like?

The thought of a laser beam scalding your buttcrack is an actual nightmare. Thankfully, this procedure is nothing like a Dr. Evil torture device.

TBH some peeps do feel pings (brief bolts of pain). Others say it feels like a hot, prickly sensation. But it should never be a kill-me-now vibe.

After the procedure, your affected skin might feel a bit sunburned or tender. This can last up to a week, usually peaking in the first 2 or 3 days.

Are there side effects?

Both DIY and professional anal bleaching can lead to uncomfortable (and sometimes permanent) side effects.

DIY risks include:

  • Genital issues: Be sure not to get products near your coochie, peen, or inside your rectum. Ouch.
  • Anal strictures: This is when scar tissue narrows the end of your anal canal, preventing your rectum from stretching. This can make pooping a real pain in the ass. It can also lead to constipation.
  • Permanent damage: Some products can scar, damage, or discolor your skin. This can also occur if you don’t follow directions and leave the solution on for too long.

Professional treatment risks include:

  • Irritation: Professionals tend to use stronger products, which can be more irritating to your skin.
  • Laser damage: This can cause permanent scarring and discoloration if done incorrectly. Always go to a certified specialist who really knows what they’re doing.
  • Skin damage: A bad treatment can leave you with permanent skin damage like scarring and discoloration.

Bleach it real good

On the hole, anal bleaching is a safe cosmetic treatment that can boost your booty confidence. But(t) keep in mind, your bum is peachy as is. If you think butthole bleaching is right for you, check out reputable providers in your area. You can also find high-quality DIY products online. 🍑


Alendronic acid - Brand names: Fosamax, Binosto, alendronate sodium, alendronate

1. About alendronic acid

Alendronic acid is a type of medicine called a bisphosphonate. Bisphosponates are prescribed to help your bones stay as strong as possible. Taking alendronic acid can help if you have, or are at risk of developing, osteoporosis. This is a condition that causes your bones to get weaker and be more likely to break.

Osteoporosis can happen for many reasons, but you are more likely to get it if:

  • you're a woman who has been through the menopause
  • you take steroids, such as prednisolone, every day for a long time (which means 3 months, or longer)
  • you've had a certain type of cancer treatment – some treatments can increase your risk of developing osteoporosis. Your oncology doctor or nurse will discuss this with you

Talk to your doctor if you are worried about the health of your bones because of the medicines you take, or changes to your hormone levels because of the menopause.

Alendronic acid is only available on prescription. You can take it as a standard tablet, a soluble tablet that dissolves in water, or as a liquid that you drink.

2. Key facts

  • Alendronic acid is good for your bones – it makes them stronger and less likely to break.
  • You'll usually take it as a tablet or liquid, once a week.
  • Take alendronic acid first thing in the morning, before you have anything to eat or drink and before you take any other medicines. Stay sitting or standing for 30 minutes so the medicine does not irritate your food pipe (oesophagus).
  • It's important to look after your teeth and have regular dental check-ups while taking alendronic acid because it can sometimes damage the jaw bone, but this is rare.
  • Alendronic acid is known as Fosavance when it's mixed with colecalciferol (vitamin D3)

3. Who can and cannot take alendronic acid

Alendronic acid can be taken by most adults aged 18 and over. It's sometimes prescribed for children with osteoporosis.

Do not give it to children under the age of 18 unless it's prescribed by a doctor.

Alendronic acid is not suitable for some people. To make sure it's safe for you, tell your doctor if you:

  • have ever had an allergic reaction to alendronic acid or any other medicine
  • have problems digesting food, swallowing or other problems with your food pipe (oesophagus)
  • have taken alendronic acid before but it made you feel dizzy and unable to stand or sit upright for at least 30 minutes after taking it
  • have low calcium levels in your blood – alendronic acid sometimes causes low blood calcium, so your calcium levels could become even lower
  • have kidney problems
  • have cancer, or are having chemotherapy or radiotherapy
  • have problems with your teeth, or are waiting for dental treatment such as having a tooth out
  • smoke, or used to smoke – this may increase your risk of dental problems
  • are pregnant, trying to get pregnant or breastfeeding

4. How and when to take alendronic acid

Follow your doctor's instructions about how and when to take your medicine.

Dosage and strength

The usual dose of alendronic acid for adults is 70mg taken once a week. There is also a 10mg tablet you take once a day.

You will usually take alendronic acid once a week:

  • as a standard tablet
  • as a liquid that you drink
  • as a tablet that dissolves in water (dispersible)

Whether you take alendronic acid daily or weekly, you need to take your medicine at the same time each day or day of the week. If it's weekly, choose smartdraw download - Crack Key For U day that suits your routine.

How to take alendronic acid

It's important to follow the instructions for this medicine very carefully. If you do not, it may not work or it could irritate and damage your food pipe as you swallow it.

The best time to take your medicine is usually 30 minutes before you have breakfast. Take it on an empty stomach, before you have anything to eat or drink (other than plain tap water) and before you take any other medicines that you swallow.

Alendronic acid works best on an empty stomach because your body can absorb it properly.

It's important to take alendronic acid while you're sitting up or standing. Try to stay upright for 30 minutes after taking your medicine – you can be sitting, standing or walking.


You can report any suspected side effect using the Yellow Card safety scheme.

Visit Yellow Card for further information.

7. Pregnancy and breastfeeding

Alendronic acid and pregnancy

Alendronic acid is not recommended during pregnancy. This is because there has not been enough research into its safety.

Alendronic acid and breastfeeding

It's generally OK to take alendronic acid while breastfeeding. This is because we only expect very small amounts to pass into breast milk. It may not be suitable in a very small number of cases. Check with your doctor about what's best for you and your baby.

Non-urgent advice: Tell your doctor if you're:

  • trying to get pregnant
  • pregnant
  • breastfeeding

For more information about how alendronic acid can affect you and your baby during pregnancy, find out more on the Best Use of Medicines in Pregnancy (BUMPS) website.

8. Cautions with other medicines

If you've been prescribed alendronic acid, do not take other medicines that you have to take by mouth (orally) at the same time. This is because it enters the stomach, soaks up the alendronic acid and stops it working properly.

If you do need to take another medicine by mouth, wait for at least 30 minutes.

Some medicines can affect the way alendronic acid works.

Tell your acid price - Crack Key For U if you're taking:

  • supplements or multivitamins containing calcium, iron, magnesium or zinc
  • antacids to relieve indigestion or heartburn
  • laxatives containing magnesium
  • cancer medicines such as bevacizumab or thalidomide
  • steroids such as prednisolone or dexamethasone – these may increase the risk of damage to your jaw bone
  • non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, which can increase the risk of irritating your food kontakt 5 player download, stomach or gut. Taking low-dose aspirin is OK
  • antibiotics such as gentamicin, amikacin or tobramycin – these can lower the calcium in your blood
  • deferasirox, a medicine used to remove excess iron from the body – this may increase the risk of bleeding from your gut

Also tell your doctor if you are having chemotherapy.

Mixing alendronic acid with herbal remedies or supplements

There's very little information about taking herbal remedies and supplements with alendronic acid.

Important: Medicine safety acid price - Crack Key For U

Tell your doctor or pharmacist if you're taking any other medicines, including herbal medicines, vitamins or supplements.

9. Common questions about alendronic acid


Phase II Drug Metabolism

Open access peer-reviewed chapter

By Petra Jančová and Michal Šiller

Submitted: March 14th 2011Reviewed: August 31st 2011Published: February 22nd 2012

DOI: 10.5772/29996

chapter and author info


  • Petra Jančová*

    • Department of Environmental Protection Engineering, Faculty of Technology, Tomas Bata University, Zlin, Czech Republic
  • Michal Šiller

    • 2Department of Acid price - Crack Key For U and Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

*Address all correspondence to:

DOI: 10.5772/29996

From the Edited Volume

Topics on Drug Metabolism

Edited by James Paxton

Show +

1. Introduction

All organisms are constantly and unavoidably exposed to xenobiotics including both man–made and natural chemicals such as drugs, plant alkaloids, microorganism toxins, pollutants, pesticides, and other industrial chemicals. Formally, biotransformation of xenobiotics as well as endogenous compounds is subdivided into phase I and phase II reactions. This chapter focuses on phase II biotransformation reactions (also called ´conjugation reactions´) which generally serve as a detoxifying step in metabolism of drugs and other xenobiotics as well as endogenous substrates. On the other hand, these conjugations also play an essential role in the toxicity of many chemicals due to the metabolic formation of toxic metabolites such as reactive electrophiles. Gene polymorphism of biotransformation enzymes may often play a role in various pathophysiological processes. Conjugation reactions usually involve metabolite activation by a high–energy intermediate and have been classified into two general types: type I (e.g., glucuronidation and sulfonation), in which an activated conjugating agent combines with substrate to yield the conjugated product, and type II (e.g., amino acid conjugation), in which the substrate is activated and then combined with an amino acid to yield a conjugated product (Hodgson, 2004). In this chapter, we will concentrate on the most important conjugation reactions, namely glucuronide conjugation, sulfoconjugation, acetylation, start menu 8 license code free 2020 acid conjugation, glutathione conjugation and methylation.


2. Phase II reactions

2.1. Glucuronidation

UDP–glucuronosyltransferases (UGTs) belong among the key enzymes of metabolism of various exogenous as well as endogenous compounds. Conjugation reactions catalyzed by the superfamily of these enzymes serve as the most important detoxification pathway for broad spectrum of drugs, dietary chemicals, carcinogens and their oxidized metabolites, and other various environmental chemicals in all vertebrates. Furthermore, UGTs are involved in the regulation of several active endogenous compounds such as bile acids or hydroxysteroids due to their inactivation via glucuronidation (Miners & McMackenzie, 1991, Kiang et al., 2005). In humans, almost 40–70% of clinically used drugs are subjected to glucuronidation (Wells et al., 2004). In general, UGTs mediate the addition of UDP-hexose to nucleophilic atom (–, –, – or – atom) in the acceptor molecule (Mackenzie et al., 2008). The UDP–glucuronic acid is the most important co–substrate involved in the conjugation reactions (called glucuronidation) carried out by UGTs. Newly formed β–D–glucuronides exhibit increased water–solubility and are easily eliminated from the body in urine or bile. The scheme of typical glucuronidation reactions is shown in Figure 1. Glucuronidation –linked moieties (acyl, phenolic, hydroxy) predominates the diversity in substrate recognition, and all of the UGTs are capable of forming –linked glucuronides, albeit with different efficiencies and turn–over rates (Tukey & Strassburg, 2000). UGTs are membrane–bound enzymes similarly to cytochromes P450 with subcellular localization in the endoplasmic reticulum (ER). In contrast to cytochromes P450, the active site of these enzymes is embedded in the lumenal part of ER.

2.1.1. Human forms of UGTs and their tissue distribution

To date, the mammalian gene superfamily comprises of 117 members. Four UGT families have been identified in humans: UGT1, UGT2 involving UGT2A and UGT2B subfamily, UGT3 and UGT8. Enzymes included in the UGT1 and UGT2 subfamily are responsible for the glucuronidation of exo– and endogenous compounds, whereas members of the UGT3 and UGT8 subfamilies have their distinct functions (See section ) (Mackenzie et al., 2008). The members of the UGT1A subfamily have been found to be identical in their terminal carboxyl 245 amino acids, which are encoded by exons 2–5. Only the uniqueness of first exon in the subfamily genes differentiates one enzyme from each other. In contrast to the UGT1A subfamily, the members of the gene subfamily contain a different set of exons (Tukey & Strassburg, 2000). The UGT enzymes of each family share at least 40% homology in DNA sequence, whereas members of UGT subfamilies exert at least 60% identity in DNA sequence (Burchell et al., 1995). As of the time of writing, 22 human UGT proteins can be distinguished: UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2A1, UGT2A2, UGT2A3, UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17, UGT2B28, UGT3A1, UGT3A2, and UGT8A1 (Mackenzie et al., 2008, Miners et al., 2006,Court et al., 2004, Patten, 2006, Sneitz et al., 2009). In general, human UGT enzymes apparently exhibit a broad tissue distribution, although the liver is the major site of expression for many UGTs. The UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15 belong among the main liver xenobiotic–conjugating enzymes, whereas UGT1A7, UGT1A8, and UGT1A10 are predominantly extrahepatic UGT forms. Moreover, glucuronidation activity was also detected in other tissues such as kidney (Sutherland et al., 1993), brain (King et al.,1999), or placenta (Collier et al., 2002).

2.1.2. UGTs substrates. Inhibition and Sony Catalyst Browse Suite 2020.1 with Crack Latest Version 2021 of UGTs

First of all, the fact that most xenobiotic metabolising UGTs show overlapping substrate specificities should be noted. Two UGTs, namely UGT8A1 and UGT3A1, stand apart from other UGT enzymes since they possess specific functions in the body. UGT8A1 takes part in the biosynthesis of glycosphingolipids, cerebrosides, and sulfatides of nerve cells (Bosio et al., 1996). Recently, the UGT3A1 enzyme has been shown to have a certain role in the metabolism of ursodeoxycholic acid used in therapy of cholestasis or gallstones (Mackenzie et al., 2008). Although many substrates (therapeutic drugs, environmental chemicals) are glucuronidated by multiple UGTs, several compounds exhibit a relative specificity towards individual UGT enzymes. Bilirubin is exclusively metabolised by UGT1A1 (Wang et al., 2006). Conjugation reactions by the UGT2B7 enzyme constitute an important step in the metabolism of opioids (Coffman et al., 1998). Carboxylic acids including several non–steroidal anti–inflammatory agents are conjugated mainly by UGT1A3, UGT1A4, UGT1A9, and UGT2B7 (Tukey & Strassburg, 2000). Acetaminophen (paracetamol) is glucuronidated predominantly by UGTs of the UGT1A subfamily (UGT1A1, UGT1A6, and UGT1A9) (Court et al., 2001). Despite the fact that in most cases UGTs are responsible for –glucuronidation of their substrates, members of the UGT1A subfamily have been found to catalyze –glucuronidation of several amine–containing substrates (chlorpromazine, amitryptyline) (Tukey & Strassburg, 2000). The intestinal UGT1A8 and UGT1A10 enzymes were suggested to have a negative impact on the bioavailability of orally administered therapeutic drugs (Mizuma, 2009). For example, raloxifene, a selective estrogen receptor modulator used in therapy of osteoporosis, naturally has a low bioavailability and has also been shown to be extensively metabolised by UGT1A8 and UGT1A10 (Kemp et al., 2002). UGTs might also play a significant role in the inactivation of carcinogens from diet or cigarette smoke (Dellinger et al., 2006). Hanioka et al. (2008) proposed that the glucuronidation of bisphenol A (an environmental endocrine disruptor) by UGT2B15 serves as a major detoxification pathway of this molecule. UGTs are notably inhibited by various compounds. Analgesics, non–steroidal anti–inflammatory drugs (NSAIDs), anxiolytics, anticonvulsants, or antiviral agents have been shown to have possible inhibitory effect on the enzymatic activities of various UGTs (thoroughly reviewed by Kiang et al., 2005). Recently, non–steroidal anti–inflammatory drugs have been shown to partially impair an equilibrium between biological functioning and degradation of aldosterone due to involvement of renal UGT2B7 in both the glucuronidation of aldosterone (deactivation) and the glucuronidation of NSAIDs (Knights et al., 2009). Similarly to other drug metabolising enzymes, UGTs are subject to induction by various xenobiotics or biologically active endogenous compounds (hormones) via nuclear receptors and transcription factors. For example, the aryl hydrocarbon receptor plays role in induction of UGT1A1 while the activation of pregnane X receptor and the constitutive androstane receptor leads to induction of UGT1A6 and UGT1A9 (Lin & Wong, 2002, Mackenzie et al., 2003, Xie et al., 2003). Several classes of drugs including analgesics, antivirals, or anticonvulsants are suspected to act as human UGTs inducers.

2.1.3. Genetic polymorphism in UGTs

Many human UGT enzymes were found to be genetically polymorphic. The mutations in gene result in several syndromes connected with decreased bilirubin detoxification capacity of UGT1A1. Kadakol et al. (2000) summed up data about more than 50 mutations of UGT1A1 causing Crigler–Najjar syndrome type I and type II. Patients suffering from type I, also called congenital familial nonhemolytic jaundice with kernicterus, completely lack the UGT1A1 enzymatic activity resulting in toxic effects of bilirubin on the central nervous system. The most common deficiency of UGT1A1 enzyme is Gilbert‘s syndrome. 2–12% of the population suffer from this benign disorder characterized by intermittent unconjugated hyperbilirubinemia. In most cases, this syndrome is caused by a mutation in the promotor region of gene (Monaghan et al., 1996). Increased toxicity of a pharmacologically active metabolite of irinotecan (SN–38) has been described in patients suffering from Gilbert’s syndrome as UGT1A1 is the main enzyme responsible for the formation of the inactive SN–38 glucuronide (Wasserman et al., 1997). The genetic variability in the or gene families was also suggested to alter risk of cancer either as a result of decreased inactivation of hormones such as estrogens or due to reduced detoxification of environmental carcinogens and their reactive metabolites (Guillemette, 2003).

2.2. Sulfoconjugation

Sulfoconjugation (or sulfonation) constitutes an important pathway in the metabolism of numerous both exogenous and endogenous compounds. The sulfonation reaction was first recognized by Baumann in 1876. Baumann detected phenyl sulfate in the urine of a patient who had been administered phenol. The sulfonation reactions are mediated by a supergene family of enzymes called sulfotransferases (SULTs). In general, these enzymes catalyze the transfer of sulfonate (SO3) from the universal sulfonate donor 3‘–phosphoadenosine 5‘–phosphosulfate (PAPS) to the hydroxyl or amino group of an acceptor molecule, Fig. 2. The incorrect term sulfation is sometimes used since sulfated products are formed in this type of reactions. PAPS is a universal donor of sulfonate moiety in sulfonation reactions and has been shown to by synthesized by almost all tissues in mammals from inorganic sulfate (Klaassen & Boles, 1997). Depletion of PAPS due to lack of inorganic sulfate or due to genetic defects of enzymes participating in PAPS synthesis may lead to reducing of sulfonation capacity which could affect the metabolism of xenobiotics or disrupt the equilibrium between synthesis and degradation of active endogenous compounds.

To date, two large groups of SULTs have been identified. The first group includes membrane–bound enzymes with no demonstrated xenobiotic–metabolising activity. These enzymes are localized in the Golgi apparatus and they are involved in metabolism of endogenous peptides, proteins, glycosaminoglycans, and lipids (Habuchi, 2000). Cytosolic SULTs constitute the second group of sulfotransferases and play a major role in conjugation of a broad spectrum of xenobiotics including environmental chemicals, natural compounds, drugs (Gamage et al., 2006) as well as endogenous compounds such as steroid hormones, iodothyronines, catecholamines, eicosanoids, retinol or vitamin D (Glatt & Meinl, 2004). Moreover, cytosolic SULTs are presumed to play a crucial role in the detoxification processes occurring in the developing human fetus since no UGTs transcripts have been detected in fetal liver at 20 weeks of gestation (Strassburg et al., 2002). Sulfonation is generally described as a detoxification pathway for many xenobiotics. Addition of the sulfonate moiety to the molecule of a parent compound or most often to the molecule of its metabolite originating in the oxidative phase of drug metabolism leads to formation of a water–soluble compound which is then easily eliminated from the body. However, in several cases the sulfonation reaction can lead to formation of a more active metabolite compared to the parent compound as is the case for the hair follicle stimulant minoxidil (Buhl et al., 1990) or the diuretic agent triamterene (Mutschler et al., 1983). Furthermore, the role of sulfotransferases in the activation of various procarcinogens and promutagens was confirmed (Gilissen et al., 1994).

2.2.1. Human forms of cytosolic SULTs and tissue distribution

In the following text we will focus only on cytosolic sulfotransferases, since this enzyme superfamily plays a key role in the biotransformation of multiple xenobiotics as well as endogenous substrates. Recently, a nomenclature system for the superfamily of cytosolic SULTs has been established analogously to those of other drug metabolising enzymes such as cytochromes P450 or UDP–glucuronosyltranferases (Blanchard et al., 2004). The superfamily of cytosolic sulfotransferases is subsequently divided into families and subfamilies according to the amino acid sequence identity among individual SULTs. In detail, members of one SULTs family share at least 45% amino acid sequence identity, whereas SULTs subfamily involves individual members with at least 60% identity. To date, four human SULT families, SULT1, SULT2, SULT4 and SULT6, have been identified. These SULT families include at least 13 different members. The SULT1 family comprises of 9 members divided into 4 subfamilies (1A1, 1A2, 1A3, 1A4, 1B1, 1C1, 1C2, 1C3 and 1E1). SULT2A (SULT2A1) and SULT2B (SULT2B1a and SULT2B1b) belong to SULT2 family. The SULT4A1 and SULT6B1 are the only members of the SULT4 and SULT6 family, respectively (Lindsay et al., 2008). Cytosolic sulfotransferases exert relatively broad tissue distribution. The members of SULT1A family were found in liver, brain, breast, intestine, jejunum, lung, adrenal gland, endometrium, placenta, kidney and in blood platelets. Figure 3 displays SULT expression “pies“ of the most important human cytosolic transferases in human tissues. SULT1A1 is predominantly expressed in the liver (Hempel et al., 2007). In contrast to SULT1A1, the SULT1A3 enzyme was not detected in human adult liver. SULT1B1 has been found in liver, small intestine, colon, and leukocytes (Wang et al., 1998). Members of SULT1C subfamily were identified in fetal human tissues such as liver (Hehonah et al., 1999) or lung and kidney (Sakakibara et al., 1998) as well as in adult human stomach (Her et al., 1997). The predominant expression of SULT1E1 was found in human liver and jejunum (Riches August 26, 2021 - Free Activators al., 2009). Major sites of SULT2A1 expression are the liver, adrenal gland, ovary, and duodenum (Javitt et al., 2001). Members of SULT2B subfamily are localized in human prostate, placenta, adrenal gland, ovary, lung, kidney, and colon (Glatt & Meinl, 2004). Recently, an exclusive localization of human SULT4A1 in the brain was confirmed (Falany et al., 2000).

2.2.2. Substrates of SULTs

SULT1A1 has been shown to be one of the most important sulfotransferases participating in metabolism of xenobiotics in humans. It has also been termed phenol sulfotransferase (P–PST) or thermostable phenol sulfotransferase (TS PST1). In general, SULT1A1 is responsible for sulfoconjugation of phenolic compounds such as monocyclic phenols, naphtols, benzylic alcohols, aromatic amines or hydroxylamines (Glatt & Meinl, 2004). Acetaminophen, minoxidil as well as dopamine or iodothyronines undergo sulfonation by SULT1A1. SULT1A1 also takes part in transformation of hydroxymethyl polycyclic aromatic hydrocarbons, –hydroxyderivatives of arylamines, allylic alcohols and heterocyclic amines to their reactive intermediates which are able to bind to nucleophilic structures such as DNA and consequently act as mutagens and carcinogens (Glatt et al., 2001). SULT1A2 also plays an important role in the toxification of several aromatic hydroxylamines (Meinl et al., 2002). SULT1A3, formerly known as thermolabile phenol SULT (TL PST) or monoamine sulfotransferase, exhibits high affinity for catecholamines (dopamine) and contributes to the regulation of the rapidly fluctuating levels of neurotransmitters. The human SULT1B1 was isolated and described by Fujita et al. (1997) and was shown to be the most important sulfotransferase in thyroid hormone metabolism. SULT1E1 plays a key role in estrogen homeostasis. This enzyme conjugates 17β–estradiol and other estrogens in a step leading to their inactivation. Since 17β–estradiol and relative compounds regulate various processes occurring in humans, inactivation of these compounds by the SULT1E1 enzyme constitute an important step in the prevention and development of certain diseases. Down regulation or loss of SULT1E1 could be to a certain extent responsible for growth of tumor in hormone sensitive cancers such as breast or endometrial cancer (Cole et al., 2010). SULT2A and SULT2B subfamilies include the hydroxysteroid sulfotransferases with partially overlapping substrate specifities. SULT2A1 is also termed as dehydroepiandrosterone sulfotransferase (DHEA ST) and conjugates various hydroxysteroids such as DHEA, androgens, bile acids and oestrone (Comer et al., 1993). Recently, a role of SULT2A1 in metabolism of quinolone drugs in humans was confirmed (Senggunprai et al., 2009). Clinically relevant substrates for other cytosolic sulfotransferases have not been identified yet.

2.2.3. Genetic polymorphisms in SULTs

Genetic polymorphism was detected in many SULT forms such as the SULT1A1, SULT1A3, SULT1C2, SULT2A1, SULT2A3 and SULT2B1 enzyme (Lindsay et al., 2008). Single nucleotide polymorphism in the gene leading to an Arg213 → His amino acid substitution is relatively frequent in the Caucasian population (25.4–36.5%) (Glatt & Meinl, 2004). This mutation results in a variation of SULT1A1 thermal stability and enzymatic activity. Several authors have claimed that SULT1A1 polymorphism might play a role in the pathophysiology of lung cancer (Arslan et al., 2009), urothelial carcinoma (Huang, 2009), and meningiomal brain tumors (Bardakci, 2008).

2.3. Glutathione conjugation

Since the first detection of glutathione transferase activity in rat liver cytosol by Booth in the early 1960s, the family of glutathione transferases (synonymously glutathione –transferases; GSTs) has been studied in detail. Undoubtedly, the members of glutathione transferase family play an important role in metabolism of certain therapeutics, detoxification of environmental carcinogens and reactive intermediates formed from various chemicals by other xenobiotic–metabolising enzymes. Furthermore, GSTs constitute an important intracellular defence against oxidative stress and they appear to be involved in synthesis and metabolism of several derivatives of arachidonic acid and steroids (van Bladeren, 2000). On the other hand, various chemicals have been shown to be activated into potentially dangerous compounds by these enzymes (Sherratt et al., 1997). In general, these enzymes catalyze a nucleophilic attack of reduced glutathione on lipophilic compounds containing an electrophilic atom (–, – or –). In addition to nucleophilic substitutions, these transferases also account for Michael additions, isomerations, and hydroxyperoxide reductions. In most cases, more polar glutathione conjugates are eliminated into the bile or are subsequently subjected to other metabolic steps eventually leading to formation of mercapturic acids. Figure 4 shows the sequential steps in the synthesis of mercapturic acids. Mercapturic acids are excreted from the body in urine (Commandeur et al., 1995). For instance, industrial chemicals such as acrylamide or trichloroethylene are detoxified via mercapturic acids (Boettcher et al., 2005, Popp et al., 1994).

2.3.1. Differentiation of GSTs, their cellular localization and tissue distribution

Up to now, two different superfamilies of GSTs have been described. The first one includes soluble dimeric enzymes localized mainly in cytosole but certain members of this superfamily have been also identified in mitochondria (Robinson et al., 2004) or in peroxisomes (Morel et al., 2004). The superfamily of human soluble GSTs is further divided into eight separate classes: Alpha (A1–A4), Kappa (K1), Mu (M1–M5), Pi (P1), Sigma (S1), Theta (T1–T2), Zeta (Z1) and Omega (O1–O2) (Hayes et al., 2005). Microsomal GSTs designated as the membrane associated proteins in eicosanoid and glutathione metabolism (MAPEG) consitute the second family of human GSTs. The human MAPEG superfamily includes six members: 5–lipoxygenase activating protein (FLAP), leukotriene C4 synthase (both involved in leukotriene synthesis), MGST1, MGST2, MGST3 (GSTs as well as glutathione dependent peroxidases) and prostaglandin E synthase (PGES) (Bresell et al., 2005). Both the soluble GSTs and MAPEG exhibit a broad tissue distribution; being found in liver, kidney, brain, lung, heart, pancreas, small intestine, prostate, spleen, and skeletal muscles (Hayes & Strange, 2000).

2.3.2. Substrates of human GSTs

Various electrophilic compounds act as substrates for GSTs. They include a broad spectrum of ketones, quinones, sulfoxides, esters, peroxides, and ozonides (van Bladeren et al., 2000). Chemotherapeutics (such as busulfan, cis–platin, ethacrynic acid, cyclophosphamide, thiotepa); industrial chemicals, herbicides, pesticides (acrolein, lindane, malathion, tridiphane) are detoxified by GSTs (Hayes et al., 2005). Epoxides and other reactive intermediates formed from environmental procarcinogens mostly as a result of metabolism by cytochromes P450 (aflatoxin B1, polycyclic aromatic hydrocarbons, styrene, benzopyrene, heterocyclic amines) also undergo detoxification by soluble GSTs. Besides their enzymatic activity, cytosolic GSTs (such as class Alpha) exhibit an ability to bind various hydrophobic ligands (xenobiotics as well as hormones) and thus contribute to their intracellular transport and disposition. GSTs play an essential role in the fight against products of oxidative stress which unavoidably damage cell membrane lipids, DNA, or proteins. Reactive intermediates resulting from lipid peroxidation (4–hydroxynonenal), nucleotide peroxidation (adenine propenal) or catecholamine peroxidation (aminochrome, dopachrome, adrenochrome) are particularly inactivated by GSTs (Dagnino–Subiabre et al., 2000). Several specific substrates for GSTs have been identified. For instance, ethacrynic acid has been found to be predominantly metabolised by GSTP1, whereas trans–stilbene oxide is a specific substrate for GSTM1 (van Bladeren, 2000). The GSTT1 enzyme is responsible for conjugation of halogenated organic compounds such as dichlormethane or ethylene–dibromide (Landi, 2000). This step leads to activation of these compounds to their reactive electrophilic metabolites with potential mutagenic and cancerogenic effect. Ethylene–dibromide, a gasoline additive and a fumigant, is presumed to be potential human carcinogen because it is transformed by GSTs to DNA–reacting episulfonium ion (van Bladeren, 2000). The glucocorticoid response element and the xenobiotic response element activated by glucocorticoids and planar aromatic hydrocarbons respectively might play a role in the induction of expression of GSTs (Talalay et al., 1988).

2.3.3. Genetic polymorphism in GSTs

Most members of both glutathione transferase superfamilies have been found to be genetically polymorphic. Several genetic variants of particular GSTs are supposed to contribute to the development of certain cancers or other diseases. Furthermore, genetic polymorphism in GSTs is pressumed to influence metabolism and disposition of various anticancerogenic drugs (Crettol et al., 2010). GSTP1 is responsible for metabolism of alkylating agents, topoisomerase inhibitors, antimetabolites, or tubulin inhibitors used in treatment of cancer. The Product Key Explorer Registration key allele is cytoprotective against the toxic effects of chemotherapeutics, whereas the functionally less competent allele is thought to increase the toxicity of anticancerogenic drugs in patients with this gene variant due to decreased metabolic activity of impaired enzyme. Cyclophosphamide is biotransformed by GSTA1. Defective allele was associated with increased survival in breast cancer patients treated with cyclophosphamide (Sweeney et al., 2003). On the other hand, several drugs activated by GSTs require a well–functioning enzyme. Patients with the active gene treated for acute myeloid leukemia with doxorubicin had a superior survival rate compared to patients with at least one null allele (Autrup et al., 2002). Individuals with lacking functional GSTM1, GSTT1, and GSTP1 have been shown to have a higher incidence of bladder, breast, colorectal, head/neck, and lung cancer. Genetically–based defects of these enzymes are also noteworthy because of their partial responsibility for increased risk of asthma, allergies, atherosclerosis, and rheumatoid arthritis (van Bladeren, 2000, Hayes et al., 2005).

2.4. Acetylation

Compared to sulfonations and glucuronidations, acetylations are modest in terms of the number and variety of substrates, but remain significant in a toxicological perspective. Drugs and other foreign compounds that are acetylated in intact animals are either aromatic amines or hydrazines, which are converted to aromatic amides and aromatic hydrazides (Parkinson, 2001). Acetylation reactions are characterized by the transfer of an acetyl moiety, the donor generally being acetyl coenzyme A, while the accepting chemical group is a primary amino function. As far as xenobiotic metabolism is concerned, three general reactions of acetylation have been documented, namely – (Fig. 5a, b),– (Fig. 5c), and –acetylations (Fig. 5d). –acetylation of aromatic amine is recognized as a major detoxification pathway in arylamine metabolism in experimental animals and humans (Hein et al., 2000). However, – and –acetylations occur in alternative metabolic pathways following activation by –hydroxylation. The resulting –acetoxyarylamines are highly unstable, spontaneously forming arylnitrenium ions that bind to DNA (Bland & Kadlubar, 1985) and ultimately lead to mutagenesis and carcinogenesis (Kerdar et al., 1993).

2.4.1. –Acetyltransferases

In humans, acetylation reactions are catalyzed by two –acetyltransferase isoenzymes (NATs), –acetyltransferase 1 (NAT1) and 2 (NAT2). NATs are cytosolic enzymes found in many tissues of various species. The human and genes are located on chromosome 8 pter–q11, and share 87% coding sequence homology (Blum et al., 1990). NAT1 and NAT2 manycam pro free distinct substrate specificities and differ markedly in terms of organ and tissue distribution. NAT2 protein is present mainly in the liver (Grant et al., 1990) and intestine (Hickman et al., 1998). NAT1 appears to be ubiquitous. Expression of human NAT1

has been detected in adult liver, bladder, digestive system, blood cells, placenta, skin, skeletal muscles, gingiva (Dupret & Lima, 2005), mammary tissue, prostate, and lung by a number of methods (Sim et al., 2008). A notable difference between the two isoenzymes is the presence of NAT1 activity in fetal and neonatal tissue, such as lungs, kidneys, and adrenal glands (Pacifici et al., 1986). By contrast, NAT2 is not evident until about 12 months after birth (Pariente–Khayat et al., 1991). NAT1 has also been detected in cancer cells, in which it may not only play a role in the development of cancers through enhanced mutagenesis but may also contribute to the resistance of some cancers to cytotoxic drugs (Adam et al., 2003). NATs are involved in the metabolism of a variety of different compounds to which we are exposed on a daily basis. In humans, acetylation is a major route of biotransformation for many arylamine and hydrazine drugs, as well as for a number of known carcinogens present in diet, cigarette smoke, car exhaust fumes, and environment in general. Human NAT1 and human NAT2 have distinct but overlapping substrate profiles and also have specific substrates which can be used as ”probe“ substrates for each particular isoenzyme. Substrates of NAT1 include –aminobenzoic acid, –aminosalicylic acid, the bacteriostatic antibiotics sulfamethoxazole and sulfanilamide, 2–aminofluorene and caffeine (Ginsberg et al., 2009). Moreover, it has been proposed by Minchin that human NAT1 plays a role in folate metabolism through the acetylation of the folate metabolite –aminobenzoylglutamate (Minchin, 1995). Human NAT2 is a xenobiotic–metabolising enzyme that provides a major route of detoxification of drugs such as isoniazid (an anti–tuberculotic drug), hydralazine and endralazine (anti–hypertensive drugs), a number of sulphonamides (anti–bacterial drugs) (Kawamura et al., 2005), procainamide (anti–arrhythmic drug), aminoglutethimide (an inhibitor of adrenocortical steroid synthesis), nitrazepam (a benzodiazepine) and the antiinflammatory drug dapsone (Ginsberg et al., 2009, Butcher at al., 2002). Both NAT1 and NAT2 are polymorphic enzymes, with 28 and 64 alleles having been identified to date (see for details of alleles; last update May 24, 2011). –acetylation polymorphism represents one of the oldest and most intensively studied pharmacogenetic traits and refers to hereditary differences concerning the acetylation of drugs and toxicants. The genetic polymorphism in NAT activity was first recognised in tuberculosis patients treated with isoniazid, which is metabolised principally by –acetylation. The polymorphism causes individual differences in the rate of metabolism of this drug. Individuals with a faster rate are called rapid acetylators and individuals with a slower rate are called slow acetylators. Rapid acetylators were competent in isoniazid acetylation but the drug was cleared less efficiently in the slow acetylator group, which resulted in elevated serum concentration and led to adverse neurologic side effects due to an accumulation of unmetabolized drug (Brockton et al., 2000). Consistent with the toxicity of isoniazid in slow acetylators, there is an increased incidence of other drug toxicities in subjects carrying defective alleles, such as lupus erythematosus in patients treated with hydralazine or procainamide (Sim et al., 1988), and haemolytic anemia and inflammatory bowel disease after treatment with sulfasalazine (Chen et al., 2007). The high frequency of the NAT2 and also NAT1 acetylation polymorphism in human population together with ubiquitous exposure to aromatic and heterocyclic amines suggest that and acetylator genotypes are important modifiers of human cancer susceptibility. Many studies suggested a relationship between acetylation phenotypes (in particular, arising from NAT2 genotypes) and the risk of various cancer including colorectal, liver, breast, prostate, head and neck (Agúndez, 2008) and other disease conditions such as birth defects (Lammer et al., 2004) or neurodegenerative and autoimmune diseases (Ladero, 2008).

2.5. Methylation

Methylation is a common but generally minor pathway of xenobiotic biotransformation. Unlike most other conjugative reactions, methylation often does not dramatically alter the solubility of substrates and results either in inactive or active compounds. Methylation reactions are primarily involved in the metabolism of small endogenous compounds such as neurotransmitters but also play a role in the metabolism of macromolecules for example nucleic acids and in the biotransformation of certain drugs. A large number of both endogenous and exogenous compounds can undergo – (Fig. 6a),– (Fig. 6b),– (Fig. 6c) and arsenic–methylation during their metabolism (Feng et al., 2010). The co–factor required to form methyl conjugates is –adenosylmethionine (SAM), which is primarily formed acid price - Crack Key For U the condensation of ATP and L–methionine.

2.5.1. –methylation

Several –methyltransferases have been described in humans and other mammals; includingwhich catalyzes the –methylation of tryptamine and structurally related compounds. The INMT exhibits wide tissue distribution. Human INMT was expressed in the lung, thyroid, adrenal gland, heart, and muscle but not in the brain (Thompson et al., 1999). Since INMT is predominantly present in peripheral tissues, its main physiological function is presumably non–neural. is a SAM–dependent cytosolic enzyme that catalyzes the –methylation of nicotinamide, pyridines, and other structural analogues. NNMT is predominantly expressed in the liver; expression has been also reported in other tissues such as the kidney, lung, placenta, and heart (Zhang et al., 2010). Several –methylated pyridines are well–established dopaminergic toxins and the NNMT can convert pyridines into toxic compounds (such as 4–phenylpyridine into methyl–4– phenylpyridinium ion [MPP+]). NNMT has been shown to be present in the human brain, a necessity for neurotoxicity, because charged compounds cannot cross the blood–brain barrier (Williams & Ramsden, 2005). NNMT was one of the potential tumor biomarkers identified in a wide range of tumors such as thyroid, gastric, colorectal, renal, and lung cancer (Zhang et al., 2010).the second most important histamine inactivating enzyme, is a cytosolic enzyme specifically methylating the imidazole ring of histamine and closely related compounds in the intracellular space of cells. Levels of HNMT activity in humans are regulated genetically. HNMT is widely expressed in human tissues; the greatest expression is in the liver and kidney, but also in the spleen, colon, prostate, ovary, brain, bronchi, and trachea (Maintz & Novak, 2007). Common genetic polymorphisms for HNMT might be related to a possible role for individual variation in histamine metabolism in the pathophysiology of diseases such as allergy, asthma, peptic ulcer disease, and some neuropsychiatric illnesses (Preuss et al., 1998). plays a role in neuroendocrine and blood pressure regulation in the central nervous system. PNMT, the terminal enzyme of the catecholamine biosynthesis pathway, catalyzes the –methylation of the neurotransmitter norepinephrine to form epinephrine (Ji et al., 2005). PNMT is a cytosolic enzyme that is present in many tissues throughout the body, with particularly high concentration in the adrenal medulla, adrenergic neurons in the amygdala and retina and the left atrium of the heart (Haavik et al., 2008). Its activity increases after stress in response to glucocorticoids and neuronal stimulation (Saito et al., 2001). Several studies have suggested that two common promoter single nucleotide polymorphisms might be associated with risk of diseases such as essential hypertension, early–onset Alzheimer’s disease, or multiple sclerosis (Ji et al., 2008). converts phosphatidylethanolamine to phosphatidylcholine in mammalian liver. Phosphatidylcholine is nutrient critical to many cellular processes such as phospholipid biosynthesis, lipid–cholesterol transport, or transmembrane signaling. The human gene encodes for two isoforms of the enzyme, namely PEMT1, which is localized in the endoplasmic reticulum and generating most of the PEMT activity, and PEMT2, a liver specific isoform exclusively localized in mitochondria–associated membranes (Tessitore et al., 2003).

2.5.2. –methylation

The process of –methylation of phenols and catechols is catalyzed by two different enzymes known as phenol –methyltransferase and catechol –methyltransferase. is an enzyme that transfers the methyl group of SAM to phenol to form anisole. POMT is a localized in the microsomes of the liver and lungs of mammals but is also present in other tissues. is a magnesium–dependent enzyme which was first described by Axelrod in 1957. It is an enzyme that plays a key role in the modulation of catechol–dependent functions such as cognition, cardiovascular function, and pain processing. COMT is involved in the inactivation of catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine, but also catecholestrogens and catechol drugs such as the anti–Parkinson´s disease agent L–DOPA and the anti–hypertensive methyldopa (Weinshilboum et al., 1999). Two forms of human COMT have been identified, a cytoplasmic soluble form (S–COMT) and a membrane–bound form (MB–COMT) located in the cytosolic side of the rough endoplasmic reticulum The S–COMT is predominantly expressed in the human liver, intestine and kidney (Taskinen et al., 2003), whereas the membrane–bound form is more highly expressed in all regions of the human central nervous system (Tunbridge et al., 2006). A common functional polymorphism at codons 108 and 158 in the genes coding for S–COMT and MB–COMT (COMT Val 108/158 Met), respectively, has been examined in relationship to a number of neurological disorders involving the noradrenergic or dopaminergic systems, such as schizophrenia (Park et al., 2002) or Parkinson's disease (Kunugi et al., 1997). It has also been suggested that a common functional genetic polymorphism in the gene may contribute to the etiology of alcoholism (Wang et al., 2001).

2.5.3. –methylation

Thiol methylation is important in the metabolism of many sulfhydryl drugs. Human tissues contain two separate genetically regulated enzymes that can catalyze thiol –methylation. is a membrane–bound enzyme that preferentially catalyzes the –methylation of aliphatic sulfhydryl compounds such as captopril and D–penicillamine, whereas is a cytoplasmic enzyme that preferentially catalyzes the –methylation of aromatic and heterocyclic sulfhydryl compounds including anticancer and immunosuppressive thiopurines such as 6–mercaptopurine, 6–thioguanine, and azathioprine. Thiopurine drugs have a relatively narrow therapeutic index and are capable of causing life–threatening toxicity, most often myelosuppression (Sahasranaman et al., 2008). TPMT genetic polymorphism represents a striking example of the clinical importance of pharmacogenetics. In 2010, 29 different variant alleles have been described (Ford & Berg, 2010) and this may be associated with large interindividual variations in thiopurine drug toxicity and therapeutic efficacy. Allele frequencies for genetic polymorphism are such that ~1 in 300 Caucasians is homozygous for a defective allele or alleles for the trait of reiboot reviews low activity, ~11% of people are heterozygous and have intermediate activity. Subjects homozygous for low TPMT activity have a high risk of myelosuppression after treatment with standard dose of azathioprine. Generally, TPMT–deficient patients (homozygous mutant) can be treated with 6–10% of the standard dose of thiopurines (Zhou, 2006). TPMT shows the highest level of expression in liver and kidney and the physiological role of this enzyme, despite extensive investigation, remains unclear.

2.5.4. –methylation

Arsenic is a well–known naturally occurring metaloid which is considered as a multiorgan human carcinogen. Occupational exposure to arsenic occurs in the smelting industry and during the manufacture of pesticides, herbicides, and other agricultural products. Arsenic plays a dual role as environmental carcinogenic pollutant and as a successful anticancer drug against promyelocytic leukemia (Wood et al., 2006). Its metabolism proceeds via a complicated enzymatic pathway, acting both as detoxification and producing more toxic intermediates. Methylation is an important reaction in the biotransformation of arsenic. Liver is considered to be the primary site for the methylation of inorganic arsenic (iAs) and is shown to be critical specifically for the arsenic metabolism, and thus may be pharmacologically important as well. Methylated and dimethylated arsenic are the major urinary metabolites in human and many other species (Li et al., 2005). Two reaction schemes (Fig. 7) have been developed to describe the individual steps in the enzymatically catalysed conversion of iAs to methylated metabolites (Thomas, 2007). Although pentavalent methylated arsenicals (MAsV, DMAsV, TMAsV) are less toxic than inorganic ones (iAsV, iAsIII), the trivalent intermediated formed during the methylation process (MAsIII, DMAsIII) are much more cytotoxic and genotoxic (Hughes, 2009).

Several single nucleotide polymorphisms in exons and introns in this gene are reported to be related to inter–individual variation in the arsenic metabolism (Fujihara et al., 2010). Polymorphism in AS3MT may influence arsenic metabolism and potentially susceptibility to its toxic and carcinogenic effects.

2.6. Amino acid conjugation reactions

The first description of glycine conjugation was published in 1842 by Keller. Xenobiotics containing a carboxyl group (–COOH) are widely used as drugs (for example simvastatin, valproic acid, or acetylsalicylic acid), herbicides, insecticides, and food preservatives. In addition, many xenobiotics are readily metabolized to carboxylic acids which may then be conjugated with acid price - Crack Key For U acids. The ability of xenobiotics to undergo amino acid conjugation depends on the steric hindrance around the carboxylic acid group, and on substituents of the aromatic ring or aliphatic side chain. Amino acid conjugation is the acid price - Crack Key For U important route of detoxification, not only for many xenobiotic carboxylic acids but also for endogenous acids. It is known that amino acid conjugation of exogenous carboxylic acids occurs in a two–step process (Reilly et al., 2007). Amino acids conjugation of carboxylic acids is a special form of acetylation and leads to amide bond formation. The most common amino acid in such reactions is glycine, and its prototypical substrate is benzoic acid, more precisely its benzoyl–CoA cofactor (Fig. 8). Bile acids are also conjugated by a similar sequence of reactions involving a microsomal cholyl–CoA synthetase and a cytosolic enzyme bile acid–CoA: amino acid –acyltransferase (Falany et al., 1994). In relation to xenobiotic carboxylic acids, amino acid conjugation involves enzymes located principally in the mitochondria of liver and kidney while conjugation of bile acids is extramitochondrial, involving enzymes located in the endoplasmic reticulum and peroxisomes (Reilly et al., 2007, Knights et al., 2007).

Glycine and glutamate appear to be the most common acceptors of amino acids in mammals. In humans, more than 95% of bile acids are –acyl amidates with glycine or taurine. Although products of amino acid conjugation are considered to be metabolically stable and nontoxic, it has been suggested that the first reaction of amino acid conjugation leads in some cases to formation of potentially toxic intermediates. This toxification pathway involves conjugation of –hydroxy aromatic amines with the carboxylic acid group of serine and proline. Amino acid activated by aminoacyl–tRNA–synthetase (Fig. 9) subsequently reacts with an aromatic hydroxylamine to form –ester that can degrade to produce a reactive nitrenium ion (Parkinson, 2001). In general, the toxicity of nitrenium ions is clinically relevant since these electrophiles possesing DNA–binding ability are responsible for carcinogenicity of aromatic amines.


3. Conclusion

Xenobiotic biotransformation is a key mechanism for maintaining homeostasis during exposure to various xenobiotics, such as drugs, industrial chemicals, or food procarcinogens. In humans and other mammals, the liver is the major site of expression of xenobiotic–metabolising enzymes, but extrahepatically localized enzymes also appear to be of great importance. In the intestine for example, several drug metabolising enzymes are presumed to decrease the bioavailability of orally administered drugs or to activate environmental carcinogens. Phase II of metabolism may or may not be preceded by Phase I reactions. Phase II enzymes undoubtedly play an important role in the detoxification of various xenobiotics. Furthermore, they significantly contribute to maintaining of homeostasis by binding, transport or inactivation of biologically active compounds such as hormones, bile acids, or other mediators. In contrast to their beneficial effects, these enzymes also participate in formation of reactive intermediates of various compounds. The most–discussed example of toxification reactions is the conjugation of –hydroxy aromatic amines. These compounds undergo activation to toxic metabolites by numerous reactions, including –glucuronidation by UGTs, –acetylation by NATs, –sulfonation by SULTs, and conjugation with amino acids by aminoacyl–tRNA–synthetase. The newly formed reactive electrophilic nitrenium and carbonium ions can act as carcinogens and mutagens due to covalent binding to DNA or to other biomolecules. Genetic polymorphisms of Phase II enzymes is another acid price - Crack Key For U issue. Impaired metabolism of drugs due to genetically based dysfunction of competent enzymes may lead to manifestation of toxic effects of clinically used drugs. Moreover, it is evident that genetic polymorphisms in these enzymes are responsible for the developement of a number of neurological disorders or cancers. In conclusion, Phase II enzymes are an interesting research field since they play an essential role in the metabolism of hundreds of foreign compounds as well as in regulation of metabolism and disposition of various endogenous biologically active substances and thus maintaining homeostasis in the human body.



Infrastructural part of this project has been supported by CZ.1.05/2.1.00/01.0030 (Biomedreg).

How to cite and reference

Cite this chapter Copy to clipboard

Petra Jančová and Michal Šiller (February 22nd 2012). Phase II Drug Metabolism, Topics on Drug Metabolism, James Paxton, IntechOpen, DOI: 10.5772/29996. Available from:

chapter statistics

13073total chapter downloads

3Crossref citations

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us

Smoking Crack

Why Do People Smoke Crack?

Crack cocaine is a stimulant that is made from powdered cocaine. Water and ammonia or baking soda are mixed with cocaine and boiled until a solid substance forms. The solid is then removed and left to dry. Once dry, the solid is broken into white chunks (rocks) and then is smoked by the user. It is typically smoked in a glass pipe or tube, called a crack pipe. Crack is easy and inexpensive to make, which makes smoking crack affordable and obtainable for many people.

Smoking crack delivers the drug straight to the lungs, which gives the user an immediate high. When the drug reaches the brain, it causes excess amounts of dopamine – a neurotransmitter linked with movement and pleasure. The high can last from 5 to 15 minutes, but once the rush abates the user will feel a desire for more of the drug. This leads to a crack addiction. Short term effects of smoking crack include hyper-stimulation, dilated pupils, constricted blood vessels, aggression, paranoia, increased breathing rate, and intense euphoria.

Difference Between Crack and Cocaine

Chemically, crack and cocaine are identical, so they produce closely matching results. The main difference is in the way they are consumed. Cocaine is usually snorted, injected, or swallowed. When cocaine is snorted, it must travel from the blood vessels in the nose to the heart, then to the lungs to be oxygenated, and then the oxygenated blood with the drug is pumped throughout the body, finally reaching the brain. Crack is smoked, skipping some asquared anti malware - Activators Patch this process and going straight to the lungs, giving the user an immediate rush. However, the effects of crack do not last as long.

Get Help During COVID-19

With just 30 days at a rehab center, you can get clean and sober, start therapy, join a support group, and learn ways to manage your cravings.

Learn More

Smoking Crack

Smoking crack is a fast and easy way to become seriously addicted to the drug. It can destroy your physical and mental health, and even first-time users can have heart attacks and seizures. Some crack addicts are unable to function sexually without the drug. The opposite is true as well; some crack cocaine addicts are unable to function sexually while using crack cocaine. Many crack users turn to prostitution, stealing, or drug dealing to be able to afford their habit. Crack and cocaine have been a major factor in many car crashes, burns, falls, drownings, and suicides. Because the drug targets the reward center of the brain, it is possible to become addicted from smoking crack one time. Some of the long-term effects of smoking crack are:

  • Delirium or psychosis
  • Hallucinations, both auditory and with the sense of touch
  • Reproductive damage
  • Severe depression
  • Frequency of risky behavior
  • Death

Looking for a place to start?

Reach out to a treatment provider for free today.

Make a Call(855) 826-4464

- OR -

Request a Call

Crack Addiction

Some signs that you or someone you know is suffering from a crack cocaine addiction are behavioral signs like changes in motivation level, academic performance, social groups, and overall attitude. Other signs include deteriorating relationships with family and friends, depression, hostility, and carelessness with grooming. According to a study published by the National Center for Biotechnology Information, smoking crack has a greater propensity for dependence and more severe consequences, compared to snorting cocaine. After entering into treatment, people who snorted cocaine had better outcomes than smokers. They remained in treatment longer and achieved longer periods of sustained abstinence than smokers. However, there was no difference in how severe the drug negatively impacted their lives.

The Prevalence of Smoking Crack in Society

A national survey states that in American adults 26 and older, 4.1% of them have tried crack in their lifetime. Only .3% have smoked crack in the past year, and .2% in the past month. The numbers are higher for snorting cocaine: over 16% of American adults have tried cocaine in their lifetime, with 1.60% of them using it in the past year. Despite the drugs being chemically identical and having similar negative effects on life, many people believe snorting cocaine is somehow better for you than smoking crack. Regardless of the way the drug is consumed, it holds the same dangerous and addictive properties.

Crack and Cocaine: Disparity in the Law

In 1986, basketball player Len Bias was selected to play in the NBA for the Boston Celtics. Hours before the draft, he died of a drug overdose. The media latched on to this story, upset and focusing on the drug that took away his bright future. The drug suspected was crack cocaine. This urged Congress to pass the Anti-Drug Abuse Act of 1986 which mandated a minimum sentence time for certain quantities of cocaine. The problem was the humongous difference in sentencing times for powdered cocaine versus crack cocaine. The sentence was a 5-year minimum for a person caught with 500 grams of powdered cocaine. For crack cocaine, it was 5 years for only 5 grams of crack. However, Bias didn’t use crack cocaine. He snorted powdered cocaine. It was too late, and the fear of crack had spread across the country, conveniently ignoring the other form of cocaine.

This created the 100:1 ratio, sending millions to prisons and jails based on the form of cocaine they used, while others walked free. Because crack is less expensive than cocaine, this law targeted lower income Americans while letting affluent drug users face less harsh punishments. Experts all agreed that crack and powdered cocaine are the same chemically, have the same effects, and one is not more dangerous than the other, but the law stayed in place for the next 24 years.

In 2010, Congress passed the Fair Sentencing Act (FSA) which reduced the sentencing disparities from 100:1 to 18:1. And in 2011, they let the FSA apply to people who were sentenced before the law came into place so a judge could review their case. Regardless of if the drug is smoked, snorted, injected, or swallowed, any form of cocaine is dangerous and addictive.

Crack Withdrawal

Unlike alcohol and heroin withdrawal, cocaine often has no physical symptoms. The come down from using the drug starts as soon as the effects wear off. The user will crave more of the drug, feel a lack of pleasure, and may feel tired, anxious, irritable, or suspicious. Symptoms of crack cocaine withdrawal include discomfort, agitation, nightmares, and depression. Cravings for the drug and depression can last for months after stopping long term heavy use. If symptoms are severe, a treatment program may be able to help and provide medications, counseling, and health monitoring.

Stop Smoking Crack Today

Even though smoking crack can lead to a powerful addiction, you can stop today. There are inpatient and outpatient rehab facilities across the country that are to providing you or your loved one with the care and support necessary to get started on the road to recovery. Contact a treatment provider to learn more about treatment options.


Notice: Undefined variable: z_bot in /sites/ on line 190

Notice: Undefined variable: z_empty in /sites/ on line 190


Leave a Comment